Tango Therapeutics

Tango Therapeutics

Tango Therapeutics launched in 2014 inside Third Rock Ventures' Boston incubator, with a founding thesis that CRISPR-powered functional genomics could expose tumor-specific vulnerabilities too subtle for traditional target discovery. Barbara Weber joined as CEO in 2017 after a career that included senior oncology development roles at Novartis and GlaxoSmithKline. The company has operated as a public clinical-stage biotech since its 2021 Nasdaq listing via a merger with a BCTG Acquisition Corp. SPAC, a vehicle backed by Boxer Capital (per SEC filings, 2021). The firm's platform identifies cancer targets through synthetic lethality — pairs of genes where loss of one is survivable, but loss of both kills the tumor cell. Tango's lead programs include TNG260, an inhibitor of a specific immune evasion target, and TNG908, a small molecule designed against a subset of solid tumors. In 2020, the company entered a collaboration with Gilead Sciences that paid $125 million upfront, with the potential for more than $400 million in milestone payments per target, giving Gilead an option on up to five programs (per SEC filings, 2020). The pipeline spans precision oncology indications in non-small cell lung cancer, pancreatic cancer, and BRCA-mutated tumors. Tango operates from a single headquarters in Boston's Seaport district. The company has not disclosed total headcount, though filings show it employed fewer than 100 people at the time of its SPAC merger. In September 2023, the firm reported dose-escalation data for TNG260 showing target engagement in patients, the first public efficacy signal for its lead program (per the firm, September 2023). Marcus Schindler, a former Novartis executive, joined the board in 2023 alongside existing board members from Third Rock Ventures. Tango's structural differentiator is its exclusive focus on a single mechanism — synthetic lethality — backstopped by a computational platform built in-house. Unlike most oncology biotechs that spread across target classes, Tango runs a discovery engine that treats the tumor genome as a map of pairwise gene interactions, looking for the second hit that collapses a cancer's survival circuit. That narrow aperture means the entire pipeline shares a common biological logic, which concentrates technical risk but gives the firm a data flywheel that compounds with each completed screen.